Michelle E. Melisko, MD; Mindy E. Goldman, MD; Jimmy Hwang, PhD; et al.
free access
has audio
JAMA Oncol. 2017;3(3):313-319. doi:10.1001/jamaoncol.2016.3904
This randomized clinical trial evaluates the safety of intravaginal testosterone cream vs an estradiol vaginal ring in patients with early-stage breast cancer receiving an aromatase inhibitor.
-
Audio Author Interview:
Comparison of Vaginal Testosterone Cream or Vaginal Ring (JAMA Oncology)
-
Editorial
Vaginal Estrogens and Aromatase Inhibitors: How Safe Is Safe Enough?
Katherine Reeder-Hayes, MD, MBA, MSCR; Hyman B. Muss, MD
JAMA Oncol
William Encinosa, PhD; Amy J. Davidoff, PhD
free access
JAMA Oncol. 2017;3(3):320-326. doi:10.1001/jamaoncol.2016.2530
This observational study provides an estimate of the baseline prevalence, trends, determinants, and costs of antiemetic overuse in patients receiving chemotherapy before and after the 2013 announcement of the Choosing Wisely guidelines.
C. Jason Wang, MD, PhD; Skye H. Cheng, MD; Jen-You Wu, MPH; et al.
free access
JAMA Oncol. 2017;3(3):327-334. doi:10.1001/jamaoncol.2016.4549
This study assesses the association of a pay-for-performance bundled-payment program vs a fee-for-service program on outcomes and medical expenditures for breast cancer in Taiwan.
Patrick G. Gavin, BS; Nan Song, PhD; S. Rim Kim, MD; et al.
free access
JAMA Oncol. 2017;3(3):335-341. doi:10.1001/jamaoncol.2016.4884
This secondary analysis of the NSABP B-31 trial evaluates the effect of FCGR2A and FCGR3A polymorphisms on trastuzumab efficacy in the adjuvant treatment of ERBB2/HER2–positive breast cancer.
Ayako Okuyama, RN, PHN, PhD; Fumiaki Nakamura, MD, PhD; Takahiro Higashi, MD, PhD
free access
JAMA Oncol. 2017;3(3):344-350. doi:10.1001/jamaoncol.2016.4096
This secondary analysis uses health insurance claims data from Japan to describe the pattern of overprescribing prophylactic antiemetic drugs to patients who have received intravenous chemotherapy.
Song Yao, PhD; Marilyn L. Kwan, PhD; Isaac J. Ergas, MPH; et al.
free access
JAMA Oncol. 2017;3(3):351-357. doi:10.1001/jamaoncol.2016.4188
This cohort study investigates the association of serum vitamin D levels at the time of diagnosis with breast cancer survival.
Zain A. Husain, MD; Tiange Chen, MPH; Christopher D. Corso, MD, PhD; et al.
free access
JAMA Oncol. 2017;3(3):358-365. doi:10.1001/jamaoncol.2016.4581
This study uses National Cancer Database data and recursive partitioning analysis to compare the prognostic ability of a new proposed staging system vs 2 other staging systems for human papillomavirus–related oropharyngeal squamous cell carcinoma.
Tahira Devji, BSc; Oren Levine, MD; Binod Neupane, PhD; et al.
free access
JAMA Oncol. 2017;3(3):366-373. doi:10.1001/jamaoncol.2016.4877
This network meta-analysis attempts to estimate the relative efficacy and safety of systemic therapies for advanced, treatment-naive, BRAF-mutated melanoma.
Anna B. Halpern, MD; Eva Culakova, PhD, MS; Roland B. Walter, MD, PhD, MS; et al.
free access
JAMA Oncol. 2017;3(3):374-381. doi:10.1001/jamaoncol.2016.4858
This longitudinal cohort study examines risk factors, mortality, length of stay, and cost associated with admission to the intensive care unit for patients with acute myeloid leukemia.
Sebastian Salas-Vega, MSc; Othon Iliopoulos, MD; Elias Mossialos, MD, PhD
free access
JAMA Oncol. 2017;3(3):382-390. doi:10.1001/jamaoncol.2016.4166
This analysis of health technology assessment reports examines the overall survival, quality of life, and safety benefits associated with recently licensed cancer medicines.
Allison W. Kurian, MD, MSc; Christopher R. Friese, PhD, RN; Irina Bondarenko, MS; et al.
free access
JAMA Oncol. 2017;3(3):391-397. doi:10.1001/jamaoncol.2016.5652
This study investigates the patterns and correlates of second opinion use and the effect on chemotherapy decisions.